Clin2
NCT06657846Likely a fitRecruiting

Quality of life and costs for people with VEXAS

VEXAS

Part of Blood & lymphatic, Genetic & congenital clinical trials.

This study looks at how VEXAS syndrome affects your daily life and finances. It aims to understand the challenges you face so doctors can better support you.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
100 people
Ages
18 years to 99 years
Study type
Observational

Who can take part

  • You are 18 years or older
  • You have a confirmed VEXAS syndrome diagnosis (genetic test showing UBA1 mutation)
  • You can give your informed consent to join
  • You do not have a serious mental health condition or major memory/thinking problems
  • You can read and understand the local language

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06538181Recruiting· Phase 1
Testing pacritinib for VEXAS syndrome

This trial tests a new drug called pacritinib for people with VEXAS syndrome, a rare autoinflammatory condition. The goal is to see if pacritinib can help control symptoms like rashes, joint pain, and low blood counts.

St Louis, Missouri
NCT06377462Recruiting
VEXAS syndrome registry with blood sample collection

This study creates a national registry for people with VEXAS syndrome to track the disease and collect blood samples for research. Joining helps doctors learn more about VEXAS so they can better diagnose and treat it in the future.

Aachen
NCT07708688Not yet recruiting
Looking for vexas syndrome in adults with unexplained inflammation

This study aims to find out how common VEXAS syndrome is and how it looks in people over 50 who have unexplained inflammation or blood issues. It helps doctors better recognize and diagnose this rare condition.

NCT07748624Recruiting· Phase 2
Testing a new drug for people with VEXAS

This study tests an investigational drug called arumakimig (MAS825) in people with VEXAS, a rare genetic condition that causes inflammation. The trial checks if the drug helps control symptoms and improve quality of life.

Yokohama, Kanagawa
NCT07569081Not yet recruiting· Phase 2/Phase 3
Momelotinib for VEXAS syndrome

This study tests whether the drug momelotinib can safely reduce inflammation and improve symptoms in people with VEXAS syndrome, a rare genetic condition. Participants will keep taking their usual steroids and may receive momelotinib or a placebo to see if it helps control the disease.

NCT06004349Recruiting
Genetic study of autoinflammatory diseases

This study looks for genes linked to autoinflammatory diseases like VEXAS syndrome. You or your family member can join by mailing in a blood or saliva sample to help researchers better understand these conditions.

New York, New York

Hear when a new VEXAS trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.